Effect of Hand Massage Stimulation on Pain and Menstrual Symptoms in Primary Dysmenorrhea

April 18, 2026 updated by: Melike TAN ÇELİK, Inonu University

Purpose of this study: The purpose of this study is to determine the effect of hand massage stimulation techniques on pain, daily menstrual symptoms and nausea and vomiting in primary dysmenorrhea.

H1a: Hand massage stimulation techniques reduce pain in primary dysmenorrhea. H1b: Hand massage stimulation techniques reduce daily menstrual symptoms in primary dysmenorrhea.

The data were collected from students suffering from primary dysmenorrhea pain studying at İnönü University Faculty of Health Sciences. Seed therapy (su-jok) will be applied by researcher Esra Tan, who has a basic level su-jok therapy certificate.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

The aim of this study is to determine the effect of hand massage stimulation techniques on pain, daily menstrual symptoms and nausea and vomiting in primary dysmenorrhea.

Data will be collected from students experiencing Primary Dysmenorrhea at İnönü University Faculty of Health Sciences. Participants who meet the inclusion criteria and agree to participate will be informed about the study, and participants who fill out the "Minimum Informed Consent Form" will be included in the study. Data collection forms will be applied by the researcher, paying attention to student privacy, and the pre-test data collection phase will be completed. After the pre-test data collection phase is completed, hand stimulation techniques (su-jok seed therapy) will be applied by the researcher to the students experiencing primary dysmenorrhea in the experimental group. Students experiencing primary dysmenorrhea will be given detailed information about the application in the laboratory at the faculty, and pain points will be determined according to the reflections of the organs on the hand. Black pepper seeds, one of the seeds used in the treatment of primary dysmenorrhea, will be placed on the detected points and removed after 5-6 hours. This application will be done a total of 3 times in each cycle, on the 1st, 2nd and 3rd day of the menstrual cycle. A total of 2 cycles of application will be made, the first menstrual cycle being the 1st cycle, and the final test data will be collected 5-6 hours after each application. This intervention will be carried out by Melike Tan, and the researcher has a basic level Su Jok therapy certificate. No intervention will be applied to the students experiencing primary dysmenorrhea in the control group, but the Personal Information Form, Visual Analog Scale (VAS), and Daily Menstrual Symptom Assessment Scale (GMDSS) will be administered simultaneously to the experimental group.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Malatya, Turkey (Türkiye)
        • İnönü University Faculty of Health Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participant who is 18 years or older
  • Participant diagnosed with primary dysmenorrhea by a gynecologist
  • Participant who has had regular menstruation in the last 6 months
  • Participant whose menstrual pain continues for 8-72 hours

Exclusion Criteria:

  • Participant who is pregnant
  • Participant who has given birth before or has a history of pregnancy
  • Participant using intrauterine or oral contraceptives
  • Participant who is taking any anti-inflammatory, analgesic and psychotherapeutic medication
  • Participant with any history of pelvic pathology or pelvic surgery
  • Participant with any neurological or systemic disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: seed therapy ( su-jok)
Group that received seed therapy ( su- jok )
In hand massage, tiny swellings called "ball conformity" occur on the reflection points of the organs where the complaint occurs on the hands and feet. It is argued that the sensitivity of the relevant point to pressure has a direct correlation with the level of pain in the body part. A rod called a "diagnostic probe" or "diagnostic rod" made of metal, plastic or wood, approximately ten centimeters long, is used to detect the painful point on the hand and foot. After the correct point is detected, various techniques are applied to stimulate these points and ensure the continuation of the energy flow.In this study, the seed massage technique, which does not cause any side effects among the hand massage stimulation methods, requires a basic level certificate for its use, does not require being a health professional, and can be easily applied by anyone, will be used. Seed massage is a method applied by first detecting pain through a probe on the points of the organs reflected on the hand
No Intervention: standard maintenance
group not receiving seed therapy ( su- jok)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual Analog Scale (VAS)
Time Frame: At baseline (pre-intervention) and immediately after completion of seed therapy]

Description: VAS is a scale created in the range of 0-10 cm. According to the scale, 0 cm means the pain is not severe at all, and 10 cm means unbearable pain. On the scale, 0-44 mm indicates mild pain, 45-74 mm indicates moderate pain, and 75-100 mm indicates severe pain.

Time Frame: At baseline (pre-intervention) and immediately after completion of seed therapy.

At baseline (pre-intervention) and immediately after completion of seed therapy]

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Daily Menstrual Symptom Assessment Scale (DMSA)
Time Frame: At baseline (pre-intervention) and immediately after completion of seed therapy]

The GMMSS was developed by Taylor in 1979 to assess symptoms and their severity during menstruation. The Turkish validity and reliability of the scale were established by Oskay et al. in 2008. The scale consists of seventeen items, with each symptom severity scored between 0 and 5, and there are no subscales. An increase in the score indicates an increase in symptom severity. In Oskay et al.'s study, the Cronbach's alpha value of the scale was found to be 0.88.

[Time Frame: Initially (before intervention) and immediately after completion of insemination treatment]

At baseline (pre-intervention) and immediately after completion of seed therapy]

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Esra GÜNEY, PhD, Inonu University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2025

Primary Completion (Estimated)

May 1, 2026

Study Completion (Estimated)

September 1, 2026

Study Registration Dates

First Submitted

April 13, 2026

First Submitted That Met QC Criteria

April 18, 2026

First Posted (Actual)

April 22, 2026

Study Record Updates

Last Update Posted (Actual)

April 22, 2026

Last Update Submitted That Met QC Criteria

April 18, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Research results will be shared

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dysmenorrhea

Clinical Trials on seed threrapy (su-jok)

Subscribe